Abstract: The success of glaucoma filtration surgery mainly depends on the scar reaction of filtration channel. The application of antimetabolites such as mitomycin C (MMC) and 5fluorouracil (5FU) can reduce filtration channel scar formation. But they still can result in a series of complications: widespread cell death and apoptosis, postoperative hypotony, thinwalled bleb, bleb leakage even endophthalmitis. How to improve the success rate of filtration surgery and reduce the postoperative complications are always concerned. Vascular endothelial growth factor (VEGF) plays an important role in promote angiogenesis, wound healing and scar formation. Recently, there are a lot of studies about using antiVEGF drug bevacizumab in the antifibotics for glaucoma surgery. This is a review about the characteristics of the VEGF, its effect on wound healing response, animal experiments and clinical studies of the application of bevacizumab alone or combines with MMC or 5FU by way of intravitreous, subconjuctival or eyedrops during glaucoma filtration surgery.  (Int Rev Ophthalmol, 2014, 38: 300-304)